Loading…
Onshoring Essential Antibiotics Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Onshoring Essential Antibiotics Act This bill requires the Department of Health and Human Services (HHS) to provide grants to up to three manufacturers of essential generic antibiotic drugs (or of the active pharmaceutical ingredient or key starting material for such a drug). Under the bill, an essential generic antibiotic drug is one that HHS deems to be medically necessary to have available at all times in adequate amounts. These grants may be used to (1) construct, expand, or upgrade a manufacturing facility in the United States; and (2) manufacture essential generic antibiotic drugs. HHS shall commission a report with (1) recommendations about which drugs should be prioritized in the grant program, and (2) an analysis of the expected effect of domestic drug manufacturing on drug costs to consumers. HHS may stockpile essential generic antibiotic drugs manufactured in the United States. The bill provides in funding for the grant program and for HHS to stockpile generic antibiotic drugs.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2024 · fourth_quarter · Health Issues
Issues related to health care workforce shortages Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus, including the Stop CMV Act (H.R. 7542/S. 3864) Issues related to funding for the allied health professional education program at the Health Resources Services Administration as expanded by Public Law 117-328) Various issues related to implementation of the ACA, including Essential Health Benefits and marketplace plans Various issues related to non-discrimination legislation and regulation Issues related to coverage of gender-affirming care/gender-affirming voice therapy Issues related to health information technology, including interoperability Issues related to funding in Fiscal Year 2025 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 1310, States Handling Access to Reciprocity for Employment Act H.R. 2663/S. 1176, the Workplace Violence Prevention for Health Care and Social Service Workers Act Issues related to coverage of hearing devices and services, including Allys Act (H.R. 2439/S. 1135) Issues related to coverage of and support for individuals who stutter through federal health programs Issues related to funding for federal health care programs, including H.R. 5894, the Fiscal Year 2024 Labor, Health and Human Services, Education and Related Agencies Act. The Long-Term Care Workforce Support Act (H.R. 7994/S. 4120) H.R. 9029, the Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025. Issues related to consolidation in the health care industry. The American Relief Act, 2025 (H.R. 10545) The Dr. Lorna Breen Health Care Provider Protection Act (H.R. 7153/S. 3679)
Client expense: $422,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Health Issues
Issues related to health care workforce shortages Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus, including the Stop CMV Act (H.R. 7542/S. 3864) Issues related to funding for the allied health professional education program at the Health Resources Services Administration as expanded by Public Law 117-328) Various issues related to implementation of the ACA, including Essential Health Benefits and marketplace plans Various issues related to non-discrimination legislation and regulation Issues related to coverage of gender-affirming care/gender-affirming voice therapy Issues related to health information technology, including interoperability Issues related to funding in Fiscal Year 2025 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 1310, States Handling Access to Reciprocity for Employment Act H.R. 2663/S. 1176, the Workplace Violence Prevention for Health Care and Social Service Workers Act Issues related to coverage of hearing devices and services, including Allys Act (H.R. 2439/S. 1135) Issues related to coverage of and support for individuals who stutter through federal health programs Issues related to funding for federal health care programs, including H.R. 5894, the Fiscal Year 2024 Labor, Health and Human Services, Education and Related Agencies Act. The Long-Term Care Workforce Support Act (H.R. 7994/S. 4120) H.R. 9029, the Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025. Issues related to consolidation in the health care industry.
Client expense: $360,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE
2024 · second_quarter · Health Issues
Issues related to health care workforce shortages Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus, including the Stop CMV Act (H.R. 7542/S. 3864) Issues related to funding for the allied health professional education program at the Health Resources Services Administration as expanded by Public Law 117-328) Various issues related to implementation of the ACA, including Essential Health Benefits and marketplace plans Various issues related to non-discrimination legislation and regulation Issues related to coverage of gender-affirming care/gender-affirming voice therapy FDA regulation of over-the-counter hearing aids Issues related to health information technology, including interoperability Issues related to funding in Fiscal Year 2025 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 1310, States Handling Access to Reciprocity for Employment Act H.R. 2663/S. 1176, the Workplace Violence Prevention for Health Care and Social Service Workers Act Issues related to coverage of hearing devices and services, including Allys Act (H.R. 2439/S. 1135) Issues related to coverage of and support for individuals who stutter through federal health programs Issues related to funding for federal health care programs, including H.R. 5894, the Fiscal Year 2024 Labor, Health and Human Services, Education and Related Agencies Act. The Long-Term Care Workforce Support Act (H.R. 7994/S. 4120)
Client expense: $290,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE
2024 · first_quarter · Health Issues
Issues related to health care workforce shortages Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus, including the Stop CMV Act (H.R. 7542/S. 3864) Issues related to funding for the allied health professional education program at the Health Resources Services Administration as expanded by Public Law 117-328) Various issues related to implementation of the ACA, including Essential Health Benefits and marketplace plans Various issues related to non-discrimination legislation and regulation Issues related to coverage of gender-affirming care/gender-affirming voice therapy FDA regulation of over-the-counter hearing aids Issues related to funding in Fiscal Year 2024 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 1310, States Handling Access to Reciprocity for Employment Act H.R. 2663/S. 1176, the Workplace Violence Prevention for Health Care and Social Service Workers Act Issues related to coverage of hearing devices and services, including Allys Act (H.R. 2439/S. 1135) Issues related to coverage of and support for individuals who stutter through federal health programs Issues related to funding for federal health care programs, including H.R. 5894, the Fiscal Year 2024 Labor, Health and Human Services, Education and Related Agencies Act. S. 4120, the Long-Term Care Workforce Support Act H.R. 2882, the Further Consolidated Appropriations Act of 2024
Client expense: $350,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE
2023 · fourth_quarter · Health Issues
Issues related to health care workforce shortages Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus Issues related to funding for the allied health professional education program at the Health Resources Services Administration as expanded by Public Law 117-328) Various issues related to implementation of the ACA, including Essential Health Benefits and marketplace plans Various issues related to non-discrimination legislation and regulation Issues related to coverage of gender-affirming care/gender-affirming voice therapy FDA regulation of over-the-counter hearing aids Issues related to funding in Fiscal Year 2024 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 1310, States Handling Access to Reciprocity for Employment Act H.R. 2663/S. 1176, the Workplace Violence Prevention for Health Care and Social Service Workers Act Issues related to coverage of hearing devices and services, including Allys Act (H.R. 2439/S. 1135) Issues related to coverage of and support for individuals who stutter through federal health programs Issues related to funding for federal health care programs, including H.R. 5894, the Fiscal Year 2024 Labor, Health and Human Services, Education and Related Agencies Act.
Client expense: $290,720 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE
2023 · third_quarter · Health Issues
Issues related to health care workforce shortages Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus Issues related to funding for the allied health professional education program at the Health Resources Services Administration as expanded by Public Law 117-328) Various issues related to implementation of the ACA, including Essential Health Benefits and marketplace plans Various issues related to non-discrimination legislation and regulation Issues related to coverage of gender-affirming care/gender-affirming voice therapy FDA regulation of over-the-counter hearing aids Issues related to funding in Fiscal Year 2024 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 1310, States Handling Access to Reciprocity for Employment Act H.R. 2663/S. 1176, the Workplace Violence Prevention for Health Care and Social Service Workers Act Issues related to coverage of hearing devices and services, including Allys Act (H.R. 2439/S. 1135) Issues related to coverage of and support for individuals who stutter through federal health programs
Client expense: $200,000 · Firm income: Not reported
2023 · second_quarter · Health Issues
Issues related to health care workforce shortages Issues related to implementation of Reeses Law (Public Law 117-171) Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus Issues related to funding for the allied health professional education program at the Health Resources Services Administration as expanded by Public Law 117-328) Various issues related to Essential Health Benefits Various issues related to non-discrimination legislation and regulation FDA regulation of over-the-counter hearing aids Issues related to implementation of surprise billing regulations Issues related to funding in Fiscal Year 2024 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 1310, States Handling Access to Reciprocity for Employment Act H.R. 2663/S. 1176, the Workplace Violence Prevention for Health Care and Social Service Workers Act Issues related to coverage of hearing devices and services, including Allys Act (H.R. 2439/S. 1135) Issues related to coverage of and support for individuals who stutter through federal health programs
Client expense: $300,000 · Firm income: Not reported
2022 · fourth_quarter · Trade (domestic/foreign)
H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Russia/Ukraine policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
Client expense: $6,610,000 · Firm income: Not reported
2022 · fourth_quarter · Health Issues
Drug Pricing Reform Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act, ASP+8 H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act
Client expense: $275,000 · Firm income: Not reported
2022 · fourth_quarter · Education
H.R 1222/S. 383, the POST Act of 2021 S.1176, the Expanding Disability Access to Higher Education Act
Client expense: $77,879 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Trade (domestic/foreign)
H.R. 1285: Requesting the President to transmit certain information to the House of Representatives relating to a waiver of intellectual property commitments under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4376, USTRx Act, provisions related to establishing a Chief Pharmaceutical Trade Negotiator H.R. 4521: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 2925: Strategic Planning for Emergency Medical Manufacturing Act - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2022 · third_quarter · Trade (domestic/foreign)
H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4521: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H. Res. 1285: Requesting the President to transmit certain information to the House of Representatives relating to a waiver of intellectual property commitments under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 2925: Strategic Planning for Emergency Medical Manufacturing Act - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Russia/Ukraine policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2022 · third_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act
Client expense: $250,000 · Firm income: Not reported
2022 · second_quarter · Trade (domestic/foreign)
H.R. 1829: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3694: To direct the Secretary of Health and Human Services, in consultation with the United States Trade Representative and other heads of Federal agencies, to submit to Congress a report the impact of a waiver of certain obligations of member nations under the Agreement on Trade-Related Aspects of Intellectual Property Rights on global COVID-19 vaccine access, and for other purposes - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3811: TRIPP Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4376, USTRx Act, provisions related to establishing a Chief Pharmaceutical Trade Negotiator H.R. 4521: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 2925: Strategic Planning for Emergency Medical Manufacturing Act - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2022 · second_quarter · Trade (domestic/foreign)
H.R. 1829: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3694: To direct the Secretary of Health and Human Services, in consultation with the United States Trade Representative and other heads of Federal agencies, to submit to Congress a report on the impact of a waiver of certain obligations of member nations under the Agreement on Trade-Related Aspects of Intellectual Property Rights on global COVID-19 vaccine access, and for other purposes - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3811: TRIPP Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4521: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act - Provisions related to medical supply chains and domestic manufacturing S. 2925: Strategic Planning for Emergency Medical Manufacturing Act - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Russia/Ukraine policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2022 · second_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act American Made Pharmaceutical Act
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2022 · first_quarter · Trade (domestic/foreign)
H.R. 1829: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4376, USTRx Act, provisions related to establishing a Chief Pharmaceutical Trade Negotiator H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4521: United States Innovation and Competition Act of 2021 H.R. 5388: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1683: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 2925: Strategic Planning for Emergency Medical Manufacturing Act - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2022 · first_quarter · Trade (domestic/foreign)
H.R. 1829: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4376, USTRx Act, provisions related to establishing a Chief Pharmaceutical Trade Negotiator H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4521: United States Innovation and Competition Act of 2021 H.R. 5388: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1683: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 2925: Strategic Planning for Emergency Medical Manufacturing Act - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2022 · first_quarter · Pharmacy
Supply Chain, S. 1176- Onshoring Essential Antibiotics Act, Pandemic Preparedness Act
Client expense: Not reported · Firm income: $40,000
Government targets: SENATE
2022 · first_quarter · Medical/Disease Research/Clinical Labs
H.R. 5602 and S. 3244 (Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act of 2021), all provisions H.R. 3932 and S. 2076 (PASTEUR Act of 2021), all provisions S. 3506 (Strengthening the Public Health Workforce Act), all provisions S. 674 (Public Health Infrastructure Saves Lives Act), all provisions S. 1176 (Onshoring Essential Antibiotics Act), all provisions H.R. 3297 (Public Health Workforce Loan Repayment Act of 2021), all provisions - Reauthorization of the Public Health Workforce Loan Repayment Program Enhancement of NIH/NIAID Physician-Scientist Training S. 3799 (PREVENT Pandemics Act), all provisions Cancer Moonshot initiative
Client expense: Not reported · Firm income: $40,000
2022 · first_quarter · Trade (domestic/foreign)
H.R. 1829: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4521: United States Innovation and Competition Act of 2021 H.R. 5388: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1683: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains S. 2740: PREPARE Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 2925: Strategic Planning for Emergency Medical Manufacturing Act - Provisions related to medical supply chains and domestic manufacturing Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues Russia/Ukraine policy issues WTO TRIPS waiver
2022 · first_quarter · Manufacturing
Monitoring legislative and regulatory efforts related to domestic manufacturing of generic drugs. S.1176 - Onshoring Essential Antibiotics Act. H.R. 5376 - Build Back Better Act. Pandemic Preparedness.
Client expense: Not reported · Firm income: $40,000
2022 · first_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act American Made Pharmaceutical Act
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2022 · first_quarter · Health Issues
H.R. 5602 and S. 3244 (Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act of 2021), all provisions; H.R. 3932 and S. 2076 (PASTEUR Act of 2021), all provisions; S. 3506 (Strengthening the Public Health Workforce Act), all provisions; S. 674 (Public Health Infrastructure Saves Lives Act), all provisions; S. 1176 (Onshoring Essential Antibiotics Act), all provisions; H.R. 3297 (Public Health Workforce Loan Repayment Act of 2021), all provisions - Reauthorization of the Public Health Workforce Loan Repayment Program; Enhancement of NIH/NIAID Physician-Scientist Training
Client expense: Not reported · Firm income: Not reported
2022 · first_quarter · Medical/Disease Research/Clinical Labs
H.R. 5602 and S. 3244 (Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act of 2021), all provisions; H.R. 3932 and S. 2076 (PASTEUR Act of 2021), all provisions; S. 3506 (Strengthening the Public Health Workforce Act), all provisions; S. 674 (Public Health Infrastructure Saves Lives Act), all provisions; S. 1176 (Onshoring Essential Antibiotics Act), all provisions; H.R. 3297 (Public Health Workforce Loan Repayment Act of 2021), all provisions - Reauthorization of the Public Health Workforce Loan Repayment Program; Enhancement of NIH/NIAID Physician-Scientist Training
Client expense: Not reported · Firm income: Not reported
2021 · fourth_quarter · Health Issues
Build Back Better Act Drug Pricing ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Pass Through Status Extension Appropriations and reach out pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake 340B Drug Pricing Program American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, White House Office
2021 · fourth_quarter · Pharmacy
Supply Chain, Onshoring, S. 1176- Onshoring Essential Antibiotics Act, Generic Drug Issues, H.R. 5376- Build Back Better Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Manufacturing
Monitoring legislative and regulatory efforts related to domestic manufacturing of generic drugs. S.1176 - Onshoring Essential Antibiotics Act. H.R. 5376 - Build Back Better Act. Pandemic Preparedness.
Client expense: Not reported · Firm income: $60,000
2021 · third_quarter · Health Issues
S.164 - Advancing Education on Biosimilars Act of 2021 Pass-Through Status Extension Medicare payments for Biosimilars Appropriations and reach out pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake 340B Drug Pricing Program American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, White House Office
2021 · third_quarter · Trade (domestic/foreign)
H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3236: AMIGOS Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3694: To direct the Secretary of Health and Human Services, in consultation with the United States Trade Representative and other heads of Federal agencies, to submit to Congress a report the impact of a waiver of certain obligations of member nations under the Agreement on Trade-Related Aspects of Intellectual Property Rights on global COVID-19 vaccine access, and for other purposes. - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3811: TRIPP Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3851: Continuous Manufacturing Research Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4121, PRO Seniors Act, provisions related to drug rebates H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4376: USTRx Act - Provisions related to international trade policy and manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1366: Pharmaceutical Supply Chain Defense and Enhancement Act - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1683: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains Trade Agreements including USMCA and related policy issues Biopharmaceutical innovation policy issues nternational intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2021 · third_quarter · Trade (domestic/foreign)
General Trade Issues. Drug Supply Chain. S.1176: Onshoring Essential Antibiotics Act. H.R.2870: Essential Medicines Strategic Stockpile Act of 2021. H.R.2653/S.1203: Medical Manufacturing, Economic Development, and Sustainability (MMEDS) Act of 2021. S.1366: Pharmaceutical Supply Chain Defense and Enhancement Act. S.1367: United States Pharmaceutical Supply Chain Review Act. AAM Blueprint to Enhance the Security of the U.S. Supply Chain. US-India Trade Discussions. TRIPS Waivers.
Client expense: $490,000 · Firm income: Not reported
2021 · third_quarter · Pharmacy
Supply Chain, Onshoring, S. 1176- Onshoring Essential Antibiotics Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Trade (domestic/foreign)
H.R. 1186: Supply Chain Security and Pharmaceutical Authentication Act of 2021 - Provisions related to medical supply chains H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3236: AMIGOS Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3682: Improving Transparency to Lower Drug Costs Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3694: To direct the Secretary of Health and Human Services, in consultation with the United States Trade Representative and other heads of Federal agencies, to submit to Congress a report the impact of a waiver of certain obligations of member nations under the Agreement on Trade-Related Aspects of Intellectual Property Rights on global COVID-19 vaccine access, and for other purposes - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3811: TRIPP Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3851: Continuous Manufacturing Research Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4295: Supply Chain Vulnerability Assessment Act of 2021 - Provisions related to medical supply chains H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4376: USTRx Act - Provisions related to international trade policy and manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1366: Pharmaceutical Supply Chain Defense and Enhancement Act - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1683: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains Trade Agreements including USMCA and related policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2021 · third_quarter · Manufacturing
Monitoring legislative and regulatory efforts related to domestic manufacturing of generic drugs. S.1176 - Onshoring Essential Antibiotics Act. The Build Back Better Act, a bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14. Pandemic Preparedness.
Client expense: Not reported · Firm income: $60,000
2021 · second_quarter · Health Issues
S.164 - Advancing Education on Biosimilars Act of 2021 Pass-Through Status Extension Medicare payments for Biosimilars Appropriations and reach out pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake 340B Drug Pricing Program American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, White House Office
2021 · second_quarter · Pharmacy
Supply Chain, Onshoring, S. 1176- Onshoring Essential Antibiotics Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Manufacturing
Monitoring legislative and regulatory efforts related to domestic manufacturing of generic drugs. S.1176 - Onshoring Essential Antibiotics Act.
Client expense: Not reported · Firm income: $60,000
2021 · second_quarter · Trade (domestic/foreign)
General Trade Issues. Drug Supply Chain. S.1176: Onshoring Essential Antibiotics Act. H.R.2870: Essential Medicines Strategic Stockpile Act of 2021. H.R.2653/S.1203: Medical Manufacturing, Economic Development, and Sustainability (MMEDS) Act of 2021. S.1366: Pharmaceutical Supply Chain Defense and Enhancement Act. S.1367: United States Pharmaceutical Supply Chain Review Act. AAM Blueprint to Enhance the Security of the U.S. Supply Chain. United States-Mexico-Canada (USMCA) Implementation. US-India Trade Discussions. TRIPS Waivers.
Client expense: $590,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Consumer Product Safety Commission (CPSC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE
Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
Client expense: $1,390,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Client expense: $7,270,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
Client expense: $1,110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Client expense: $6,340,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Client expense: $1,100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Client expense: $830,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Client expense: $8,070,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Client expense: $1,200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $7,440,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)